Back to top
more

Prothena (PRTA)

(Delayed Data from NSDQ)

$20.87 USD

20.87
369,975

+0.31 (1.51%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $20.87 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline

by Zacks Equity Research

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?

by Zacks Equity Research

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug

by Zacks Equity Research

Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.

Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense

by Zacks Equity Research

Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.

Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Prothena's (PRTA) Update on Pipeline Progress Disappoints

by Zacks Equity Research

Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.

Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity

by Zacks Equity Research

Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog.

Ekta Bagri headshot

Alzheimer's Disease Space Evolves in 2023: Stocks in Focus

by Ekta Bagri

The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.

Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market

by Zacks Equity Research

Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.

Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

by Zacks Equity Research

Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.

Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of 246.15% and 63.68%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 Biotech Stocks Set to Outpace Q3 Earnings Estimates

by Zacks Equity Research

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Annovis (ANVS) AD Study to Continue as Planned, Shares Rise

by Zacks Equity Research

Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficiently powered to continue as planned without any additional patients.

Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why

by Zacks Equity Research

Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.

Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.

Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of -11.96% and 62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression

by Zacks Equity Research

Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.

Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment

by Zacks Equity Research

Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.

Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY

by Zacks Equity Research

Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.

Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's

by Zacks Equity Research

Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.